Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.
The ACCC rejected a $3 million settlement offer in a high-profile case against the Construction, Forestry, Mining, and Energy Union over secondary boycotts, instead taking its chances in a trial that ultimately resulted in a penalty of just $1 million, according to a judgment published Friday.
A technology company has won dismissal of a Federal Court case alleging its industrial machine safety system that uses laser beams to detect hazards infringed on a patent licensed to a rival.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
A judge has rejected Amaca’s bid for indemnity costs in a case over contributions to an asbestos class action settlement, but he did not rule on the company’s novel argument that a settlement resulting from mediation could count as the outcome of litigation in awarding costs.
Vodafone will have to cough up $295,000 to cover the legal bills of the ACCC and Telstra after falling short in its bid for judicial review of an ACCC decision not to declare a domestic mobile roaming service.
Domestic roaming is not the answer to sub-par mobile phone coverage in regional Australia, the competition watchdog has said in a big win for Telstra.